Investor Overview

Webcast ImageWebcast
Q2 2010 Elan Corporation, plc Earnings Conference Call (Replay)
07/22/10 at 8:30 a.m. ET
Q2 2010 Elan Corporation, plc Earnings Conference Call
Thursday, July 22, 2010 8:30 a.m. ET  
Webcast PresentationHelp Help
Listen to the Webcast in Windows Media Player Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Company Overview:

 

Elan is a neuroscience-based biotechnology company headquartered in Dublin, Ireland. It was incorporated as a private limited company in December 1969 and became a public limited company in January 1984. Elan’s principal research and development, manufacturing and marketing facilities are located in Ireland and the United States.

Elan is organized into two business units: BioNeurology and Elan Drug Technologies.

BioNeurology includes research, development, and commercial activities for neurodegenerative diseases and autoimmune diseases. Elan Drug Technologies is a specialty pharmaceutical business, including specialized drug delivery and manufacturing.

What's New:

 
2009 Annual Report

Stock Quote:

 
ELN (ADS Common)
PriceChange% ChangeVolume
$4.77 + 0.040.85%1,692,132
Previous CloseToday's OpenIntraday HighIntraday Low
$4.73$4.67$4.77$4.65
07/30/10 4:03 p.m. ET
Minimum 20 minute delay

Recent Financial News:

More >>

 
22 July 2010
Elan Reports Second Quarter and First Half 2010 Financial Results
DUBLIN, Jul 22, 2010 (BUSINESS WIRE) -- Elan Corporation, plc today reported its second quarter and first half 2010 financial results. Elan CEO Kelly Martin commented, "Our second quarter results demonstrate continued progress across our major areas of focus. Tysabri growth increased in terms of net patient additions; our BioNeurology pipeline advanced, including completion of the ELND005 Phase 2 trial and full enrollment of the STRATIFY 1 trial studying the JC virus assay; we also saw recen... 
15 July 2010
Elan Corporation, plc Reaches Agreement in Principle for Settlement of Investigation of Past Zonegran Sales and Marketing Activities
Elan establishes $206.3 million reserve for expected settlement DUBLIN, Jul 15, 2010 (BUSINESS WIRE) --Elan Corporation, plc (NYSE: ELN) today announced that it has reached an agreement in principle with the United States Attorney's Office for the District of Massachusetts with respect to the previously disclosed U.S. Department of Justice's investigation of sales and marketing practices for Zonegran (zonisamide), an antiepileptic prescription medicine that ... 
08 July 2010
Elan Announces Webcast of Second Quarter 2010 Financial Results
DUBLIN, Jul 08, 2010 (BUSINESS WIRE) --Elan Corporation, plc (NYSE:ELN) announced today that it will host a conference call on Thursday, July 22, at 8:30 a.m. Eastern Time (ET), 1:30 p.m. GMT with the investment community to discuss Elan's second quarter 2010 financial results, which will be released before the European and U.S. financial markets open. Live audio of the conference call will be simultaneously broadcast over the Internet and will be ava... 
06 July 2010
Eliseo O. Salinas, MD, MSc Joins Elan as Executive Vice President and Chief Medical Officer
DUBLIN, Jul 06, 2010 (BUSINESS WIRE) --Elan Corporation, plc (NYSE: ELN) today announced that Eliseo Oreste Salinas, MD, MSc, has joined the company as Executive Vice President and Chief Medical Officer effective immediately, with responsibility for leading the company's global development, clinical and medical initiatives. Dr. Salinas will be based at Elan's South San Francisco campus, will be a member of the company's executive leadership team, and ... 

Upcoming Events:

More >>

 
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Elan Corporation, PLC posts new information to the site. Just enter your e-mail address and click Submit.
 
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts Contact IR